digest

February 12, 2026

2026-02-12
3 itemsX×3
X

@tbpn: “This is going to be a trillion-dollar drug.” @hubermanlab says retatrut…

@tbpnbookmarkx

TL;DR. Huberman calls retatrutide a "trillion-dollar drug" after Phase III trials showed up to 33% body weight loss in six months.

Takeaways

  • Retatrutide drove ~1/3 body weight loss in 6 months — a step-change beyond current GLP-1s like Ozempic/Mounjaro.
  • Still in Phase III; "some degree of muscle" loss hinted at but cut off in the clip.
X

@bwarrn: Last year, I gave up on my YC-backed company. I would’ve done it earli…

@bwarrnbookmarkx

TL;DR. A YC founder explains he should've quit his funded startup sooner — co-founder fit mattered more than the brand, money, or paper-perfect setup.

Takeaways

  • YC pedigree and funding don't compensate for a mismatched co-founder relationship.
  • "On paper, everything was set up perfectly" — the most dangerous kind of startup, because the external validation delays the hard internal call.
  • Sunk-cost thinking around YC status likely kept him in longer than was rational.